Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences:
Live webcasts will be available in the investor section of the company's website at www.epizyme.com. The webcasts also will be archived for 60 days following the call and presentation.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage
biopharmaceutical company committed to rewriting treatment for cancer
and other serious diseases through novel epigenetic medicines. Epizyme
is broadly developing its lead product candidate, tazemetostat, a
first-in-class EZH2 inhibitor, with studies underway in both solid
tumors and hematological malignancies, as a monotherapy and combination
therapy in relapsed and front-line disease. The company also is
developing a novel G9a program with its next development candidate,
EZM8266, which is targeting sickle cell disease. By focusing on the
genetic drivers of disease, Epizyme's science seeks to match targeted
medicines with the patients who need them. For more information, visit www.epizyme.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005160/en/
Media:
Erin Graves, (617) 500-0615
Epizyme, Inc.
media@epizyme.com
Investors:
Monique Allaire, (617) 896-9511
THRUST
Strategic Communications
monique@thrustsc.com